A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice

Pérez, José Luís; Acevedo, Reinaldo; Callicó, Adriana; Fernández, Yovania; Cedré, Bárbara; Año, Gemma; González, Lissette; Falero, Gustavo; Talavera, Arturo; Pérez, Óliver; Garcı́a, Luis

doi:10.1016/j.vaccine.2008.10.052

Cited by 22 publications

(16 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…V. cholerae O1 proteoliposomes were the first vesicles (OMV C ) obtained at the Finlay Institute from enteric pathogens. Figure 1 shows a micrograph of OMV C from Perez et al which demonstrated that these vesicles induced an antibody response with vibriocidal activity when administered via the nasal route (37). An OMV C extraction process was developed with sodium dodecyl sulfate (SDS) detergent to achieve maximum recovery of LPS from the bacteria.…”

Section: Omv Vaccines Against Enteric Pathogensmentioning

confidence: 99%

“…An OMV C extraction process was developed with sodium dodecyl sulfate (SDS) detergent to achieve maximum recovery of LPS from the bacteria. Protein antigens with vaccine potential, such as OmpU and MSHA, were also found in OMV C (37). In an alternative approach, Schild et al obtained nOMV C using a detergent-free method and demonstrated that intranasal and oral administration of these vesicles were immunogenic and protective in a model where the offspring of immunized female mice were infection challenged (38).…”

Section: Omv Vaccines Against Enteric Pathogensmentioning

confidence: 99%

“… Schematic representation of the dOMV extraction process and two micrographs of OMV obtained using this technology with two different detergents: OMV from N. meningitidis serogroup B extracted with deoxycholate (10) and OMV from V. cholerae O1 extracted with sodium dodecyl sulfate (37) . OMV have a similar size and vesicle like structure.…”

Section: Omv Vaccines Against Enteric Pathogensmentioning

confidence: 99%

See 2 more Smart Citations

Bacterial Outer Membrane Vesicles and Vaccine Applications

et al. 2014

Self Cite

View full text Add to dashboard Cite

Vaccines based on outer membrane vesicles (OMV) were developed more than 20 years ago against Neisseria meningitidis serogroup B. These nano-sized structures exhibit remarkable potential for immunomodulation of immune responses and delivery of meningococcal antigens or unrelated antigens incorporated into the vesicle structure. This paper reviews different applications in OMV Research and Development (R&D) and provides examples of OMV developed and evaluated at the Finlay Institute in Cuba. A Good Manufacturing Practice (GMP) process was developed at the Finlay Institute to produce OMV from N. meningitidis serogroup B (dOMVB) using detergent extraction. Subsequently, OMV from N. meningitidis, serogroup A (dOMVA), serogroup W (dOMVW), and serogroup X (dOMVX) were obtained using this process. More recently, the extraction process has also been applied effectively for obtaining OMV on a research scale from Vibrio cholerae (dOMVC), Bordetella pertussis (dOMVBP), Mycobacterium smegmatis (dOMVSM), and BCG (dOMVBCG). The immunogenicity of the OMV has been evaluated for specific antibody induction, and together with functional bactericidal and challenge assays in mice has shown their protective potential. dOMVB has been evaluated with non-neisserial antigens, including with a herpes virus type 2 glycoprotein, ovalbumin, and allergens. In conclusion, OMV are proving to be more versatile than first conceived and remain an important technology for development of vaccine candidates.

show abstract

Section: Omv Vaccines Against Enteric Pathogensmentioning

confidence: 99%

Section: Omv Vaccines Against Enteric Pathogensmentioning

confidence: 99%

Section: Omv Vaccines Against Enteric Pathogensmentioning

confidence: 99%

See 1 more Smart Citation

Bacterial Outer Membrane Vesicles and Vaccine Applications

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…Proteoliposomes can also be used as effective mucosal adjuvants. Intranasal administration of proteoliposomes containing LPS into mice led to high anti-LPS IgG titers [194]. Similarly, intranasal administration of proteoliposomes (AFPL1; 70 nm in size) containing glycoprotein D (gD) of herpes simplex virus type 2 (HSV-2) induced gD-specific IgG antibody formation, leading to partial protection against genital herpes infection in mice [190].…”

Section: Liposomes/proteoliposome/virosomesmentioning

confidence: 99%

Selection of Adjuvants for Enhanced Vaccine Potency

Wang¹,

Singh²

2011

WJV

View full text Add to dashboard Cite

show abstract

“…At the present, only one cholera vaccine, Dukoral, is internationally licensed and available [7], and mOROVAC (http://www.vabiotechvn.com) is used only in Vietnam [8]. Some vaccine projects are in development, such as the attenuated vaccines Peru 15, CVD 110, 111 and 112 strains [9] and 638 strain [10]) and the inactivated whole cells and subunit vaccines [11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Is cholera disease associated with poverty?

Talavera

Pérez

2009

J Infect Dev Ctries

Self Cite

View full text Add to dashboard Cite

Background: Cholera remains a global threat and is one of the key indicators of social development. While the disease no longer poses a menace to countries with minimum standards of hygiene, it remains a serious challenge to countries where access to safe drinking water and adequate sanitation cannot be guaranteed. The objective of this work was to analyse the results obtained when contrasting the reports of the World Health Organization (WHO) about cholera disease with those of the World Bank List of economies (countries). Methodology: Data were obtained from reports of two international organizations, the report on cholera disease incidence of the World Health Organization and the World Bank's classification of countries attending to their income. Results: We determined that low-income countries are more affected by cholera disease than countries with middle or high income. This difference was reflected in the percent of countries, the total number of reported cases, the number of cases per 100,000 habitants, as well as in the reported mortality. These results support the phrase "cholera disease is a disease of poverty." Conclusions: We consider that economic development is an important factor in the morbidity and mortality of cholera, together with environment, climate, culture, medical management, political intention, and the intrinsic factors of the system.

show abstract

A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice

Cited by 22 publications

References 42 publications

Bacterial Outer Membrane Vesicles and Vaccine Applications

Bacterial Outer Membrane Vesicles and Vaccine Applications

Selection of Adjuvants for Enhanced Vaccine Potency

Is cholera disease associated with poverty?

Contact Info

Product

Resources

About